Anagrelide (Agrylin) is a selective antiplatelet agent primarily used for the treatment of thrombocythemia secondary to myeloproliferative neoplasms. It reduces the risk of thrombosis and improves related symptoms by lowering platelet count.
How to Use Anagrelide (Agrylin)
Dosage Regimen
Adults: The initial dose is 0.5 mg four times daily or 1 mg twice daily. Capsules should be swallowed whole.
Children (≥ 7 years old): The initial dose is 0.5 mg once daily.
Maintenance Dose: The initial dose should be maintained for at least 1 week before gradual adjustment. The weekly dose increase should not exceed 0.5 mg/day, with a single dose not exceeding 2.5 mg and a total daily dose not exceeding 10 mg.
Dose Adjustment of Anagrelide (Agrylin)
Adjustment Based on Platelet Response
Monitoring Frequency: Platelet count should be monitored weekly in the early stage of treatment; after reaching the target, monitoring can be changed to monthly or as needed.
Adjustment Principle: If the platelet count fails to reach the target (> 600,000/μL), the dose can be increased by 0.5 mg/day weekly until therapeutic effect is achieved.
The effective dose for most patients is 1.5 - 3.0 mg/day.
Rebound After Discontinuation: When treatment is interrupted, platelets may increase again within 4 days and return to baseline levels within 1 - 2 weeks, requiring close monitoring.
Adjustment for Patients with Hepatic Impairment
Moderate Hepatic Impairment (Child - Pugh 7 - 9 points): The initial dose should be reduced to 0.5 mg/day, and the subsequent weekly dose increase should not exceed 0.5 mg/day.
Severe Hepatic Impairment: Use should be avoided.
Precautions for Medication Use in Special Populations of Anagrelide (Agrylin)
Children and Adolescents
Safety: Adverse reactions in children aged ≥ 7 years are similar to those in adults (such as headache, fever, and epistaxis), but heart rate and blood pressure fluctuations need to be monitored.
Pharmacokinetic Differences: Pediatric doses need to be individualized, as plasma drug concentrations in children may be higher than those in adults.
Pregnancy and Lactation
Pregnancy: Animal studies have shown fetal developmental delay, and human data are limited. The risk of thrombosis and potential fetal effects should be weighed.
Lactation: The drug can pass into rat milk. It is recommended to avoid breastfeeding during treatment and within 1 week after drug discontinuation.
Patients with Hepatic or Renal Impairment
Hepatic Impairment: Dose reduction is required for patients with moderate hepatic impairment, and use is contraindicated for those with severe hepatic impairment.
Renal Impairment: No dose adjustment is needed for patients with severe renal impairment (CrCl < 30 mL/min).
